Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price upped by Barclays from $917.00 to $1,075.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective indicates a potential upside of 12.24% from the company’s previous close.
A number of other research analysts have also recently commented on the stock. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Leerink Partners boosted their price objective on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the stock a “market perform” rating in a research report on Monday, November 2nd. Raymond James Financial boosted their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. HSBC boosted their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Piper Sandler increased their price target on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $904.41.
View Our Latest Stock Report on REGN
Regeneron Pharmaceuticals Stock Up 0.6%
Shares of REGN traded up $5.40 during trading hours on Tuesday, hitting $957.80. 303,229 shares of the company were exchanged, compared to its average volume of 835,621. The firm’s 50 day moving average is $818.67 and its 200-day moving average is $748.36. Regeneron Pharmaceuticals has a 52 week low of $591.52 and a 52 week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. The company has a market cap of $99.08 billion, a PE ratio of 21.16, a PEG ratio of 1.26 and a beta of 0.10.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter last year, the firm posted $11.83 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 58.26 EPS for the current fiscal year.
Insider Activity
In other news, EVP Joseph Larosa sold 4,466 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the sale, the executive vice president owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. This represents a 10.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $900.00, for a total value of $360,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at $542,700. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 27,028 shares of company stock valued at $25,025,950. Company insiders own 6.97% of the company’s stock.
Institutional Trading of Regeneron Pharmaceuticals
A number of large investors have recently bought and sold shares of REGN. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $26,000. Armstrong Advisory Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. Trust Co. of Vermont bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. Finally, Fiduciary Financial Advisors purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Further Reading
- Five stocks we like better than Regeneron Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
